Cheng-Pin Chen to Female
This is a "connection" page, showing publications Cheng-Pin Chen has written about Female.
Connection Strength
0.030
-
A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). PLoS One. 2020; 15(12):e0242763.
Score: 0.012
-
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021 04 15; 12(1):2349.
Score: 0.003
-
Multicenter evaluation of four immunoassays for the performance of early diagnosis of COVID-19 and assessment of antibody responses of patients with pneumonia in Taiwan. J Microbiol Immunol Infect. 2021 Oct; 54(5):816-829.
Score: 0.003
-
Clinical validation of an automated reverse transcription-insulated isothermal PCR assay for the detection of severe acute respiratory syndrome coronavirus 2. J Microbiol Immunol Infect. 2021 Jun; 54(3):522-526.
Score: 0.003
-
Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan. Emerg Microbes Infect. 2020 Dec; 9(1):2157-2168.
Score: 0.003
-
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. J Microbiol Immunol Infect. 2020 Jun; 53(3):488-492.
Score: 0.003
-
Early Seroreversion After 2 Doses of Hepatitis A Vaccination in Human Immunodeficiency Virus-Positive Patients: Incidence and Associated Factors. Hepatology. 2019 08; 70(2):465-475.
Score: 0.003